BioMarin Pharmaceuticals BMRN Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- BioMarin Pharmaceuticals (BMRN) reported finite-lived intangible assets, accumulated amortization of $517.7M in Q1 2026.
- How has BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization changed year-over-year?
- BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization increased by 9.3% year-over-year, from $473.76M to $517.7M.
- What is the long-term trend for BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's finite-lived intangible assets, accumulated amortization has grown at a 17.6% compound annual growth rate (CAGR), from $226.82M to $510.13M.